Alvotech/$ALVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
Ticker
$ALVO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Luxembourg, Luxembourg
Employees
1,012
ISIN
LU2458332611
Website
Alvotech Metrics
BasicAdvanced
$2.7B
25.78
$0.34
0.19
-
Price and volume
Market cap
$2.7B
Beta
0.19
52-week high
$13.70
52-week low
$7.35
Average daily volume
220K
Financial strength
Current ratio
1.726
Quick ratio
1.006
Long term debt to equity
-391.392
Total debt to equity
-405.888
Interest coverage (TTM)
0.85%
Profitability
EBITDA (TTM)
147.647
Gross margin (TTM)
60.74%
Net profit margin (TTM)
16.42%
Operating margin (TTM)
22.02%
Effective tax rate (TTM)
4.43%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
7.02%
Return on equity (TTM)
-20.09%
Valuation
Price to earnings (TTM)
25.785
Price to revenue (TTM)
4.115
Price to book
-8.13
Price to tangible book (TTM)
-7.34
Price to free cash flow (TTM)
-10.769
Free cash flow yield (TTM)
-9.29%
Free cash flow per share (TTM)
-81.16%
Growth
Revenue change (TTM)
413.92%
Earnings per share change (TTM)
-115.98%
3-year revenue growth (CAGR)
146.40%
3-year earnings per share growth (CAGR)
2.20%
Bulls say / Bears say
Alvotech's revenue surged by 426.84% in 2024, reaching $491.98 million, indicating strong market demand for its biosimilar products. (stockanalysis.com)
Analysts have set a 12-month price target of $18.00 for ALVO, suggesting a potential upside of over 100%. (stockanalysis.com)
The company has secured a European supply and commercialization agreement for its biosimilar candidate to Cimzia® (certolizumab pegol), expanding its market presence. (stockanalysis.com)
Alvotech's stock has entered oversold territory with an RSI reading of 29.4, indicating potential bearish momentum. (nasdaq.com)
The company reported a net loss of $231.86 million in 2024, highlighting ongoing profitability challenges. (stockanalysis.com)
Potential U.S. import tariffs on Icelandic manufacturing could adversely affect Alvotech's cost structure and profitability. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Alvotech News
AllArticlesVideos
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
GlobeNewsWire·15 hours ago
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
GlobeNewsWire·15 hours ago
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland
GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alvotech stock?
Alvotech (ALVO) has a market cap of $2.7B as of July 10, 2025.
What is the P/E ratio for Alvotech stock?
The price to earnings (P/E) ratio for Alvotech (ALVO) stock is 25.78 as of July 10, 2025.
Does Alvotech stock pay dividends?
No, Alvotech (ALVO) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Alvotech dividend payment date?
Alvotech (ALVO) stock does not pay dividends to its shareholders.
What is the beta indicator for Alvotech?
Alvotech (ALVO) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.